Investor relations

We are a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics

Our proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates very often administered post surgically.

Nasdaq: PRFX

3.10

CHANGE: -1.90%

DAILY VOLUME: 210,949

LAST UPDATE: 04-22-2021 00:00

our numbers

Up to

72

hours post-operatively

Phase

3

Clinical Trial

2007

Founded

US

$12B

Post-operative pain treatment overall market

*2017

US

$45B

future post-operative pain treatment overall market

*is expected to reach by the end of 2026

Over

40-45

million procedures in the US per year

media

Send us a Message